Characteristics and Outcome of Exertional Heatstroke Patients Complicated by Acute Hepatic Injury: A

来源 :临床与转化肝病杂志(英文版) | 被引量 : 0次 | 上传用户:youwdw
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background and Aims: Exertional heatstroke (EHS) is as-sociated with strenuous physical activity in hot environments. The present study aimed to investigate dynamic changes of hepatic function indices in EHS patients and determine risk factors for death. Methods: This single-center retrospective cohort study considered all patients with EHS admitted to the intensive care unit at the General Hospital of Southern Theater Command of PLA from October 2008 to May 2019. Data on general characteristics, organ function parameters, and the 90-day outcome of enrolled patients were collected. Hepatic indices were collected dynamically, and patients with acute hepatic injury (AHI) were identified by plasma total bil-irubin (TBIL) ≥34.2 μmol/L and an international normalized ratio ≥1.5, or with any grade of hepatic encephalopathy. Re-sults: In patients who survived, TBIL, alanine aminotrans-ferase and aspartate aminotransferase were increased at 24 h, peaked at 2-3 days, and began to decrease at 5 days. In non-survivors, TBIL continuously increased post-admission. The area under the receiver operating characteristic curve for the prediction of mortality based on sequential organ failure assessment (SOFA) scores was 89.8%, and the optimal cut-off value was 7.5. Myocardial injury and infection were iden-tified as independent risk factors for death in EHS patients with AHI. Conclusions: In EHS patients, hepatic dysfunction usually occurred within 24 h. Patients with AHI had more severe clinical conditions, and significantly increased 90-day mortality rates. SOFA scores over 7.5, complicated with myo-cardial injury or infection, were found to be risk factors for death in EHS patients with AHI.
其他文献
Background and Aims: There are no comparative studies on the efficacy of hepatic resection (HR) and CyberKnife stereotactic body radiation therapy (CK-SBRT) plus tran-shepatic arterial chemotherapy embolization (TACE) in the treatment of large hepatocellu
Background and Aims: Spontaneous bacterial peritonitis (SBP) is one of the leading causes of death in patients with liver cirrhosis. We aimed to establish a prognostic model to evaluate the 1-year survival of cirrhosis patients after the first episode of
Background and Aims: The pathogenesis of liver fibrosis involves liver damage, inflammation, oxidative stress, and intestinal dysfunction. Indole-3-propionic acid (IPA) has been demonstrated to have antioxidant, anti-inflammatory and anticancer activities
Background and Aims: Endovascular implantation of io-dine-125 (125I) seeds strand combined with stent is an effec-tive method of treatment for portal vein tumor thrombosis. The aim of this study was to develop a novel endovascular brachytherapy stent (EVB
Background and Aims: Acute liver failure (ALF) is an inflam-matory process of acute liver cell injury. Mesenchymal stem cells (MSCs) are undifferentiated, primitive cells with anti-inflammatory, anti-apoptotic, and multi-directional differen-tiation abili
The diagnosis of metabolic-associated fatty liver disease is based on the detection of liver steatosis together with the presence of metabolic dysfunction. According to this new defi-nition, the diagnosis of metabolic-associated fatty liver disease is ind
Nonalcoholic fatty liver disease (NAFLD) affects about a quar-ter of the world\'s population and poses a major health and economic burden globally. Recently, there have been hasty attempts to rename NAFLD to metabolic-associated fatty liv-er disease (MA
Metabolic dysfunction-associated fatty liver disease (com-monly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and eco-nomic burden is enormous. While much attention has been given to metabolic syndro
Background and Aims: The efficacy of targeted pro-grammed cell death 1/programmed death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) has been confirmed in many solid malignant tumors. The overexpression of PD-1/PD-L1 serves as a biomarker to predict
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease and affects at least a quarter of the global adult population. It has rapidly become one of the leading causes of hepa-tocellular carcinoma a